Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
This study is designed to determine the clinical efficacy and toxicity of ABT 869 in the
treatment of subjects with advanced renal cell carcinoma who have previously received
treatment with sunitinib.